{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:02:30Z","timestamp":1784592150282,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":59,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Funding for this trial was provided by the Victorian Cancer Agency."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cancer cachexia is a multifactorial syndrome characterised by involuntary weight loss and muscle wasting, commonly seen in patients with advanced malignancies. Lean Body Mass (LBM) assessment is crucial for the early indentification and monitoring of cancer cachexia. Dual-energy X-ray absorptiometry (DEXA) is widely accepted as the gold standard for evaluating body composition. This study aims to develop a method for estimating LBM using whole-body low-dose CT acquired during PET\/CT imaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A cohort of patients enrolled in a prospective pilot study on cancer cachexia were included in the analysis. All patients underwent both DEXA and [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT imaging. Lean body mass was assessed by calculating the Total Body Lean Mass ratio (TBLMr) from DEXA (TBLMr\n                      <jats:sub>DEXA<\/jats:sub>\n                      ) and also whole-body low-dose CT (TBLMr\n                      <jats:sub>CT<\/jats:sub>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 32 (13-cachectic, 19-non-cachectic) patients with advanced malignancies were included in the analysis. The TBLMr\n                      <jats:sub>CT<\/jats:sub>\n                      and TBLMr\n                      <jats:sub>DEXA<\/jats:sub>\n                      were highly correlated (R\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.92). Bland-Altman plots indicated a scaling bias with increasing TBLMr\n                      <jats:sub>DEXA<\/jats:sub>\n                      values, with the non-cachectic group exhibiting a tighter distribution (0.06\u2009\u00b1\u20090.05) compared to the cachectic group (0.03\u2009\u00b1\u20090.11). TBLMr values were significantly different between cachectic and non-cachectic groups for both the DEXA-derived (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.004) and low-dose CT-derived (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.010) measurements.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Whole-body low-dose CT obtained from routine [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT imaging can provide an accurate estimate of LBM, showing high concordance with DEXA-derived measurements and clinical diagnosis of cachexia. This method offers a practical method for monitoring cancer cachexia in patients undergoing routine [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT scans.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40644-026-01047-3","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T05:14:57Z","timestamp":1779513297000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Lean body mass using whole-body low-dose Ct from Pet\/Ct to identify cancer Cachexia"],"prefix":"10.1186","volume":"26","author":[{"given":"G. J.","family":"O\u2019Keefe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Senko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. J.","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fogliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ninatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Pathmaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Burvenich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Osellame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hoogenraad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"1047_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-023-01454-0","volume":"16","author":"T Setiawan","year":"2023","unstructured":"Setiawan T, Sari IN, Wijaya YT, et al. Cancer cachexia: molecular mechanisms and treatment strategies. J Hematol Oncol. 2023;16:54.","journal-title":"J Hematol Oncol"},{"key":"1047_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489\u201395.","journal-title":"Lancet Oncol"},{"key":"1047_CR3","doi-asserted-by":"publisher","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","volume":"4","author":"VE Baracos","year":"2018","unstructured":"Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Primers. 2018;4:17105.","journal-title":"Nat Rev Dis Primers"},{"key":"1047_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1200\/JOP.2016.016832","volume":"12","author":"AR Bruggeman","year":"2016","unstructured":"Bruggeman AR, Kamal AH, LeBlanc TW, Ma JD, Baracos VE, Roeland EJ. Cancer Cachexia: Beyond Weight Loss. JOP. 2016;12:1163\u201371.","journal-title":"JOP"},{"key":"1047_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/diagnostics11010116","volume":"11","author":"E Berardi","year":"2021","unstructured":"Berardi E, Madaro L, Lozanoska-Ochser B, et al. A Pound of Flesh: What Cachexia Is and What It Is Not. Diagnostics (Basel). 2021;11:116.","journal-title":"Diagnostics (Basel)"},{"key":"1047_CR6","first-page":"305","volume":"55","author":"LGC Chaves","year":"2022","unstructured":"Chaves LGC, de Gon\u00e7alves M, Bitencourt TJM, Rstom AGV, Pereira RA, Velludo TR. Assessment of body composition by whole-body densitometry: what radiologists should know. Radiol Bras. 2022;55:305\u201311.","journal-title":"Radiol Bras"},{"key":"1047_CR7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13550-021-00834-2","volume":"11","author":"J Han","year":"2021","unstructured":"Han J, Harrison L, Patzelt L, et al. Imaging modalities for diagnosis and monitoring of cancer cachexia. EJNMMI Res. 2021;11:94.","journal-title":"EJNMMI Res"},{"key":"1047_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.semcdb.2015.09.001","volume":"54","author":"SMR Kazemi-Bajestani","year":"2016","unstructured":"Kazemi-Bajestani SMR, Mazurak VC, Baracos V. Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes. Semin Cell Dev Biol. 2016;54:2\u201310.","journal-title":"Semin Cell Dev Biol"},{"key":"1047_CR9","doi-asserted-by":"publisher","first-page":"e0291185","DOI":"10.1371\/journal.pone.0291185","volume":"19","author":"E Khristenko","year":"2024","unstructured":"Khristenko E, Sinitsyn V, Rieden T, et al. CT-based screening of sarcopenia and its role in cachexia syndrome in pancreatic cancer. PLoS ONE. 2024;19:e0291185.","journal-title":"PLoS ONE"},{"key":"1047_CR10","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.21037\/jgo-21-556","volume":"12","author":"Z Kang","year":"2021","unstructured":"Kang Z, Cheng L, Li K, et al. Correlation between L3 skeletal muscle index and prognosis of patients with stage IV gastric cancer. J Gastrointest Oncol. 2021;12:2073\u201381.","journal-title":"J Gastrointest Oncol"},{"key":"1047_CR11","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.2147\/CMAR.S195869","volume":"11","author":"D Portal","year":"2019","unstructured":"Portal D, Hofstetter L, Eshed I, et al. L3 skeletal muscle index (L3SMI) is a surrogate marker of sarcopenia and frailty in non-small cell lung cancer patients. Cancer Manag Res. 2019;11:2579\u201388.","journal-title":"Cancer Manag Res"},{"key":"1047_CR12","doi-asserted-by":"publisher","first-page":"S1133","DOI":"10.3945\/ajcn.2010.28608C","volume":"91","author":"VE Baracos","year":"2010","unstructured":"Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S. Body composition in patients with non\u2013small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis1234. Am J Clin Nutr. 2010;91:S1133\u20137.","journal-title":"Am J Clin Nutr"},{"key":"1047_CR13","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2967\/jnumed.115.164913","volume":"57","author":"P Decazes","year":"2016","unstructured":"Decazes P, M\u00e9tivier D, Rouquette A, Talbot J, Kerrou K. A Method to Improve the Semiquantification of 18F-FDG Uptake: Reliability of the Estimated Lean Body Mass Using Conventional, Low-Dose CT from PET\/CT. J Nucl Med. 2016;57:753\u20138.","journal-title":"J Nucl Med"},{"key":"1047_CR14","doi-asserted-by":"crossref","unstructured":"Miller RJH, Yi J, Shanbhag A et al. Deep learning-quantified body composition from positron emission tomography\/computed tomography and cardiovascular outcomes: a multicentre study. European Heart Journal March 2025:ehaf131.","DOI":"10.1093\/eurheartj\/ehaf131"},{"key":"1047_CR15","doi-asserted-by":"publisher","first-page":"21597","DOI":"10.1038\/s41598-024-71878-2","volume":"14","author":"DY Lee","year":"2024","unstructured":"Lee DY, Oh JS, Kim JW, et al. Comparative analysis of body composition using torso CT from PET\/CT with bioelectrical impedance and muscle strength in healthy adults. Sci Rep. 2024;14:21597.","journal-title":"Sci Rep"},{"key":"1047_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/ajcn\/36.1.172","volume":"36","author":"G Borkan","year":"1982","unstructured":"Borkan G, Gerzof S, Robbins A, Hults D, Silbert C, Silbert J. Assessment of abdominal fat content by computed tomography. Am j Clin Nutr. 1982;36:172\u20137.","journal-title":"Am j Clin Nutr"},{"key":"1047_CR17","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2967\/jnmt.119.236109","volume":"48","author":"I Sarikaya","year":"2020","unstructured":"Sarikaya I, Sarikaya A. Assessing PET Parameters in Oncologic 18F-FDG Studies. J Nucl Med Technol. 2020;48:278\u201382.","journal-title":"J Nucl Med Technol"},{"key":"1047_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2967\/jnmt.119.233353","volume":"48","author":"I Sarikaya","year":"2020","unstructured":"Sarikaya I, Albatineh AN, Sarikaya A. Revisiting Weight-Normalized SUV and Lean-Body-Mass-Normalized SUV in PET Studies. J Nucl Med Technol. 2020;48:163\u20137.","journal-title":"J Nucl Med Technol"},{"key":"1047_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40658-020-00290-2","volume":"7","author":"S Vandenberghe","year":"2020","unstructured":"Vandenberghe S, Moskal P, Karp JS. State of the art in total body PET. EJNMMI Phys. 2020;7:35.","journal-title":"EJNMMI Phys"},{"key":"1047_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1053\/j.semnuclmed.2024.07.003","volume":"55","author":"RJ Hicks","year":"2025","unstructured":"Hicks RJ, Ware RE, Callahan J, Total-Body PETCT. Pros and Cons. Semin Nucl Med. 2025;55:11\u201320.","journal-title":"Semin Nucl Med"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01047-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01047-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01047-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:08:50Z","timestamp":1784588930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01047-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1047"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01047-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8090492\/v1","asserted-by":"object"}]},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants provided written informed consent prior to inclusion. The study received approval from the local Institutional Review Board and was sponsored by the Olivia Newton-John Cancer Research Institute. The trial was registered on ClinicalTrials.gov (NCT04127981\u2013 Registration date 28th March 2019).","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have provided consent.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"88"}}